At the inception of the study, patients with relapsed/refractory acute leukemia, regardless of cytogenetic and mutational profile, could enroll; however, enrollment was subsequently restricted to KMT2A‐r and NPM1mut leukemia given the strong evidence that those biological subsets critically depend on the Menin–KMT2A interaction. The gene discussed is KMT2A; the disease is leukemia.